Surpassing several setbacks, the clinical development of antiangiogenic agents has accelerated remarkably over the past 3–4 years. As a result, there are currently three direct blockers of the VEGF ...pathway approved for use in cancer, and two others for age-related wet macular degeneration. Other agents that block the VEGF pathway are currently in advanced stages of clinical development and have shown promising results. With these exciting developments come critical questions regarding the use of these new molecularly targeted agents, alone or in combination with standard cytotoxic or targeted agents.
As an antitumor agent, interleukin-12 (IL-12) has been revealed to be a key regulator of the immune response, particularly that involving CTL and natural killer (NK) cells. We report herein the ...antiangiogenesis effect of IL-12 on human as well as murine tumors in NK-depleted severe-combined immunodeficient mice using fibroblasts genetically engineered to secrete this cytokine. Although the in vitro growth of tumor cells was not affected by the presence of IL-12, coinoculation of IL-12-secreting fibroblasts strongly inhibited tumor growth in immunodeficient mice. The neovascularization surrounding the tumor was remarkably inhibited in the area in which the IL-12-secreting fibroblasts were implanted, resulting in the suppression of tumor growth. Lectin staining in tumor sample sections also showed a significant reduction in the number of vessels. The RNA expression of IFN-gamma and its inducible antiangiogenic chemokine IFN gamma-inducible protein 10 was stimulated in endothelial cells cultured with IL-12. It was also found that IL-12 down-regulated the expression of the endothelial cell mitogens vascular endothelial growth factor and basic fibroblast growth factor. The antitumor effects of IL-12 were accompanied by interesting histological changes consisting of a high degree of keratinization and apoptosis and a decrease in the proliferation rate of human tumors and extensive necrosis in the murine ones.
Solid tumors require blood vessels for growth, and many new cancer therapies are targeted against the tumor vasculature. The widely held view is that these antiangiogenic therapies destroy the tumor ...vasculature, thereby depriving the tumor of oxygen and nutrients. Indeed, that is the ultimate goal of antiangiogenic therapies. However, emerging preclinical and clinical evidence support an alternative hypothesis, that judicious application of agents that block angiogenesis directly (e.g., bevacizumab, AZD2171) and indirectly (e.g., trastuzumab) can also transiently “normalize” the abnormal structure and function of tumor vasculature. In addition to being more efficient for oxygen and drug delivery, the normalized vessels are fortified with pericytes, which can hinder intravasation of cancer cells, a necessary step in hematogenous metastasis. Drugs that induce vascular normalization can also normalize the tumor microenvironment—reduce hypoxia and interstitial fluid pressure—and thus increase the efficacy of many conventional therapies if both are carefully scheduled. Reduced interstitial fluid pressure can decrease tumor-associated edema as well as the probability of lymphatic dissemination. Independent of these effects, alleviation of hypoxia can decrease the selection pressure for a more malignant phenotype. Finally, the increase in proliferation of cancer cells during the “vascular normalization window” can potentially sensitize tumors to cytotoxic agents. Our recent Phase II clinical trial in glioblastoma patients shows that the normalization window— identified using advanced magnetic resonance imaging (MRI) techniques—can last one to four months, and the resulting changes in tumor vasculature correlate with circulating molecular and cellular biomarkers in these patients.
Solid tumors require blood vessels for growth, and many new cancer therapies are targeted against the tumor vasculature. The widely held view is that these antiangiogenic therapies destroy the tumor ...vasculature, thereby depriving the tumor of oxygen and nutrients. Indeed that is the ultimate goal of antiangiogenic therapies. However, emerging preclinical and clinical evidence support an alternative hypothesis, that judicious application of agents that block angiogenesis directly (e.g., bevacizumab and cediranib) and indirectly (e.g., trastuzumab) can also transiently “normalize” the abnormal structure and function of tumor vasculature. In addition to being more efficient for oxygen and drug delivery, the normalized vessels are fortified with pericytes, which can hinder intravasation of cancer cells, a necessary step in hematogenous metastasis. Drugs that induce vascular normalization can also normalize the tumor microenvironment—reduce hypoxia and interstitial fluid pressure—and thus increase the efficacy of many conventional therapies if both are carefully scheduled. Reduced interstitial fluid pressure can decrease tumor-associated edema as well as the probability of lymphatic dissemination. Independent of these effects, alleviation of hypoxia can decrease the selection pressure for a more malignant phenotype. Finally, the increase in proliferation of cancer cells during the “vascular normalization window” can potentially sensitize tumors to cytotoxic agents. Results from our recent phase II clinical trial of cediranib, an oral, pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) in glioblastoma patients, show that the normalization window—identified using advanced magnetic resonance imaging (MRI) techniques—can last 1–4 months, and the resulting changes in tumor vasculature correlate with blood circulating molecular and cellular biomarkers in these patients. Antiangiogenic therapies may provide benefit for cancer patients by working through different mechanisms at different points in time. Normalization may be an early consequence of antiangiogenic therapy and offers an opportunity for optimizing delivery and facilitating the cytotoxic effects of chemotherapy and radiation. However, additional consequences of antiangiogenic therapies may include vessel “pruning” and nutrient deprivation of tumors.
Pancreatic cancer has a poor prognosis even when surgical treatment can be accomplished. Studies have demonstrated that pancreatic cancer is associated with various genetic abnormalities in oncogenes ...and tumor suppressor genes including p53. New therapeutic approaches for pancreatic cancer can be developed by targeting these genetic alterations. Adenovirus (Adv) lacking the 55-kDa E1B protein (E1B55K) replicates preferentially in p53-deficient cancer cells. We constructed E1B55K-deleted Adv (AxE1AdB), and studied its replication and cytopathic effect on pancreatic cancer cells. AxE1AdB replicated in and caused cell death of the p53-deficient pancreatic cancer cell lines tested (e.g., PANC-1, MIAPaCa-2, SU.86.86, BxPC-3, and PK-1). To enhance its therapeutic effect, we examined the combination of coinfecting this restricted replication-competent adenovirus (RRCA) with other Adv. Coinfection of E1-deficient Adv expressing the reporter lacZ gene (AxCAlacZ) together with AxE1AdB resulted in the replication of both viruses and a marked increase in reporter gene expression. PANC-1 cells coinfected with AxE1AdB and the Adv for human IL-2 (AxCAhIL2), produced 110 times more IL-2 than those infected with AxCAhIL2 alone. Similarly, coinfection of AxE1AdB and Adv for human IL-12 augmented the IL-12 production by 370-fold. Injecting AxE1AdB into the PANC-1 tumor of severe combined immunodeficient mice (SCID mice) resulted in marked reduction of the volume of the tumor. Moreover, injecting AxE1AdB with AxCAhIL2 into the PANC-1 tumor resulted in complete regression of the established tumors. These data suggest that RRCA, which augments the antitumor effect of a viral transgene (i.e., cytokines), may be a powerful tool for treating p53-deficient pancreatic cancer.